“We're expecting the final national coverage from CMS on or before October 8, and we expect the U.S. launch of our Symplicity procedure for hypertension to ramp after that.”

In context

“lerate growth in each of our segments in the second half of the year. In our earnings deck that we posted earlier today, we outlined several milestones that we have coming over the rest of the fiscal year that will drive this acceleration, the largest, of course, being our CAS business with our continued rollout of our PFA portfolio. In Q2, we expect our CAS business to grow even faster than the nearly 50% growth we posted this past quarter. And we continue to have near-term line of sight to adding an incremental $1 billion in revenue off of our fiscal '25 base. Demand remains extremely high, and we're executing against our plans to quickly ramp mapping system and catheter supply. And CAS is just one of several upcoming growth accelerators for cardiovascular. Let's talk Renal Denervation. We're expecting the final national coverage from CMS on or before October 8, and we expect the U.S. launch of our Symplicity procedure for hypertension to ramp after that. And our Peripheral Vascular business will start the launch of our Contego carotid stent system this quarter and our Liberant mechanical thrombectomy system in the second half of the fiscal year. Now in Neuroscience, we're poised to accelerate growth starting this quarter with further acceleration in the back half of the fiscal year. First, we expect our Pelvic Health business to be a key driver for this segment in fiscal '26 and beyond. Importantly, ahead of our tibial launch this fall, we took the opportunity to make some significant changes to our commercial organization in Pelvic Health in Q1. Now while this had some short-term impact in the quarter as we expected, it sets us up. It sets us up to capitalize on the large opportunity ahead as we anticipate accelerating growth from this b”